Refractory hyperkalaemia due to trimethoprim, successfully treated with fludrocortisone.
We report a case of intractable hyperkalaemia in an elderly patient with myeloma, who received conventional dose of trimethoprim-sulfamethoxazole and hyperkalaemia resolved following therapy with fludrocortisone. We recommend monitoring of serum potassium in high-risk patients receiving conventional doses of trimethoprim-sulfamethoxazole for 5 or more days.
Sanjay
S
S
Departments of Nephrology, Apollo Hospitals, Chennai, India.
Annigeri
R A
RA
Gopalakrishnan
R
R
D000368:Aged; D000890:Anti-Infective Agents / Q000009:adverse effects*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D005438:Fludrocortisone / Q000627:therapeutic use; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced* / Q000188:drug therapy; D008297:Male; D009101:Multiple Myeloma / Q000150:complications; D012307:Risk Factors; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects*
D000890:Anti-Infective Agents; D000893:Anti-Inflammatory Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D005438:Fludrocortisone